Cytokinetics Inc

CYTK

Healthcare|Biotechnology|USA

$84.87

-1.18 (-1.37%)

Upcoming Data Readouts (5)

Sep 2026

Est. completion

P2Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Dec 2026

Est. completion

P4Hypertrophic Cardiomyopathy (HCM)

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Mar 2027

Est. completion

Hypertrophic Cardiomyopathy (HCM)

HCMR Re-Imaging Study

Sep 2027

Est. completion

P3Heart Failure

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Jan 2030

Est. completion

P2P3Pediatric

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM